Data Mining of Adverse Reactions to Iodinated Contrast Media Based on a Municipal Spontaneous Reporting System in China

Abstract

Objective

Iodinated contrast media (ICM) are widely used in medical imaging, particularly in computed tomography (CT) and magnetic resonance imaging (MRI) examinations, to increase image quality and improve diagnostic accuracy. Despite their clinical utility, ICM are associated with various adverse drug reactions (ADRs), including allergic reactions and other systemic effects. This study aimed to evaluate ICM-related ADRs through the Chinese spontaneous reporting system (SRS) and provide reference information for clinical practice.

Methods

We analyzed ADRs related to ICM on the basis of data from the SRS in Wuhan, China, from January 1, 2018, to December 31, 2023.

Results

A total of 2,166 ADR reports related to four ICM (iodixanol, iohexol, ioversol, and iomeprol) were analyzed to assess the proportion and severity of adverse reactions. The results revealed that the majority of the ADRs were mild, with the most common symptoms being rash (54.76%) and itching (35.18%). Gastrointestinal and respiratory symptoms were also noted, although less frequently. Anaphylactic shock was documented in 48 patients, accounting for 9.69% of severe adverse reactions. The incidence of ADRs was greater in summer. Circulatory system diseases were the most prevalent underlying conditions in patients who experienced ADRs. Treatment primarily involved symptomatic management, including corticosteroids and antihistamines, with adrenaline administered in severe cases.

Conclusions

This study highlights the importance of monitoring high-risk patients, especially elderly patients and those with preexisting conditions, and underscores the need for timely intervention in severe reactions. Future prospective studies are necessary to facilitate the selection of more appropriate ICM for individual patients.

Keywords

Iodinated contrast media / Adverse drug reactions / Spontaneous reporting system

References

[1] Huynh K, Baghdanian AH, Baghdanian AA, et al.. Updated guidelines for intravenous contrast use for CT and MRI. Emerg Radiol., 2020, 27(2): 115-126

[2] Huang L, Luo Y, Chen ZL, et al.. Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system. Heliyon., 2023, 9(11 e21694

[3] Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol., 2001, 11(7): 1267-1275

[4] Costa C, Abeijon P, Rodrigues DA, et al.. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm., 2023, 45(6): 1349-1358

[5] Yu D, Vydiswaran VGV. An Assessment of Mentions of Adverse Drug Events on Social Media With Natural Language Processing: Model Development and Analysis. JMIR Med Inform., 2022, 10(9 e38140

[6] Lin X, Yang J, Weng L, et al. Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. J Allergy Clin Immunol Pract. 2023;11(5):1494–1502 e1496.

[7] Li X, Chen J, Zhang L, et al.. Clinical observation of the adverse drug reactions caused by non-ionic iodinated contrast media: results from 109,255 cases who underwent enhanced CT examination in Chongqing, China. Br J Radiol., 2015, 88(1047): 20140491

[8] Cha MJ, Kang DY, Lee W, et al.. Hypersensitivity Reactions to Iodinated Contrast Media: A Multicenter Study of 196 081 Patients. Radiology., 2019, 293(1117-124

[9] Jiang C, Li J, Huang Y, et al.. Clinical safety evaluation of contrast agents based on real-world evidence. J Clin Pharm Ther., 2021, 46(6): 1600-1605

[10] Hershkowitz I, Moss J, Sosna J, et al.. Iodinated Contrast Media Allergy and Its Management in a Large Cohort in the Hospital Setting. Isr Med Assoc J., 2025, 27(1): 42-48

[11] Zeng W, Tang J, Xu X, et al.. Safety of non-ionic contrast media in CT examinations for out-patients: retrospective multicenter analysis of 473,482 patients. Eur Radiol., 2024, 34(9): 5570-5577

[12] Zhang J, Liu H, Li J, et al.. Adverse reactions to iodinated contrast media in patients with a history of allergies. Clin Radiol., 2025, 82 106771

[13] McDonald JS, Larson NB, Schmitz JJ, et al.. Acute Adverse Events After Iodinated Contrast Agent Administration of 359,977 Injections: A Single-Center Retrospective Study. Mayo Clin Proc., 2023, 98(12): 1820-1830

[14] Chatani R, Kondo S, Kamimura T, et al.. Exploring Factors Affecting the Occurrence of Hypersensitivity Reactions Induced by Nonionic Iodine Contrast Media. J Clin Pharmacol., 2023, 63(9): 1002-1008

[15] Tsushima Y, Seki Y, Nakajima T, et al.. The effect of abolishing instructions to fast prior to contrast-enhanced CT on the incidence of acute adverse reactions. Insights Imaging., 2020, 11(1): 113

[16] Gamboa P, Sanchez de Vicente J, Galan C, et al. Non-immediate hypersensitivity reactions to iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media. Allergy. 2022;77(12):3641–3647.

[17] Bednarczuk T, Kajdaniuk D, Marek B, et al.. Basics of prevention and management of iodine-based contrast media-induced thyroid dysfunction - position paper by the Polish Society of Endocrinology. Endokrynol Pol., 2023, 74(11-4

[18] Teoh WC. Preventing recurrent hypersensitivity reactions to iodinated contrast media. Ann Acad Med Singap., 2023, 52(3): 114-115

[19] Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol., 2021, 147(4): 1123-1131

[20] Egbert RE, De Cecco CN, Schoepf UJ, et al.. Delayed adverse reactions to the parenteral administration of iodinated contrast media. AJR Am J Roentgenol., 2014, 203(6): 1163-1170

[21] Fukushima Y, Taketomi-Takahashi A, Suto T, et al.. Clinical features and risk factors of iodinated contrast media (ICM)-induced anaphylaxis. Eur J Radiol., 2023, 164 110880

[22] Bianchi L, Hansel K, Biondi F, et al.. Delayed hypersensitivity reactions to iodinated contrast media: A diagnostic approach by skin tests. Contact Dermatitis., 2023, 89(5): 352-358

[23] Rosado Ingelmo A, Dona Diaz I, Cabanas Moreno R, et al. Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media. J Investig Allergol Clin Immunol. 2016;26(3):144–155.

[24] Caimmi S, Benyahia B, Suau D, et al.. Clinical value of negative skin tests to iodinated contrast media. Clin Exp Allergy., 2010, 40(5): 805-810

[25] Torres MJ, Gomez F, Dona I, et al.. Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. Allergy., 2012, 67(7): 929-935

[26] Torres MJ, Trautmann A, Bohm I, et al.. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy., 2021, 76(5): 1325-1339

[27] Bansie RD, Karim AF, van Maaren MS, et al.. Assessment of immediate and non-immediate hypersensitivity contrast reactions by skin tests and provocation tests: A review. Int J Immunopathol Pharmacol., 2021, 35: 20587384211015061

[28] McDonald JS. Contrast Agent Substitution to Prevent Repeat Adverse Reactions. Radiology., 2022, 305(2): 350-352

[29] Ahn YH, Koh YI, Kim JH, et al.. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity. J Korean Med Sci., 2015, 30(3245-251

RIGHTS & PERMISSIONS

The Author(s)